Cited by 538Blood Pressure and Hypertension StudiesHeart Rate Variability and Autonomic ControlCardiovascular Syncope and Autonomic Disorders

The human sympathetic nervous system: its relevance in hypertension and heart failure

Open access
Parati, G., Esler, M.·2012·European Heart Journal

Abstract

Evidence assembled in this review indicates that sympathetic nervous system dysfunction is crucial in the development of heart failure and essential hypertension. This takes the form of persistent and adverse activation of sympathetic outflows to the heart and kidneys in both conditions. An important goal for clinical scientists is translation of the knowledge of pathophysiology, such as this, into better treatment for patients. The achievement of this 'mechanisms to management' transition is at different stages of development with regard to the two disorders. Clinical translation is mature in cardiac failure, knowledge of cardiac neural pathophysiology having led to the introduction of beta-adrenergic blockers, an effective therapy. With essential hypertension perhaps we are on the cusp of effective translation, with recent successful testing of selective catheter-based renal sympathetic nerve ablation in patients with resistant hypertension, an intervention firmly based on the demonstration of activation of the renal sympathetic outflow. Additional evidence in this regard is provided by the results of pilot studies exploring the possibility to reduce blood pressure in resistant hypertensives through electrical stimulation of the area of carotid baroreceptors. Despite the general importance of the sympathetic nervous system in blood pressure regulation, and the specific demonstration that the blood pressure elevation in essential hypertension is commonly initiated and sustained by sympathetic nervous activation, drugs antagonizing this system are currently underutilized in the care of patients with hypertension. Use of beta-adrenergic blocking drugs is waning, given the propensity of this drug class to have adverse metabolic effects, including predisposition to diabetes development. The blood pressure lowering achieved with carotid baroreceptor stimulation and with the renal denervation device affirms the importance of the sympathetic nervous system in hypertension pathogenesis, and perhaps suggests a wider role for anti-adrenergic antihypertensives, such as the imidazoline drug class (moxonidine, rilmenidine) which act within the CNS to inhibit central sympathetic outflow, although the lack of large-scale outcome trials with this drug class remains a very material deficiency.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/eurheartj/ehs041

Cites

84 of 84 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 4

  1. von Euler US. A specific sympathetic ergone in adrenergic nerve fibres (sym- pathin) and its relation to adrenaline and noradrenaline. Acta Physiol Scand 1946;12:73-97.
  2. Friberg P, Meredith I, Jennings G, Lambert G, Fazio V, Esler M. Evidence of increased renal noradrenaline spillover rate during sodium restriction in man. Hypertension 1990;16:121 -130.
  3. Goldberger JJ, Cain ME, Hohnloser SH, Kadish AH, Knight BP, Lauer MS, Maron BJ, Page RL, Passman RS, Siscovick D, Stevenson WG, Zipes DP. American Heart Association/American College of Cardiology Foundation/Heart Rhythm Society Scientific Statement on Noninvasive Risk Stratification Techniques for Identifying Patients at Risk for Sudden Cardiac Death. Circulation 2008;118: 1497 -1518.
  4. Esler M. Looking at the sympathetic nervous system as a primary source. In: Zanchetti A, Robertson JIS, Birkenhager WH, eds, Handbook of Hypertension: Hypertension Research in the Twentieth Century. Amsterdam: Elsevier, 2004. p81 -103.

Cited by

Sorted by citations

Authors
Parati, G., & Esler, M.
Affiliations
  • IRCCS Istituto Auxologico Italiano (IT)
  • Baker Heart and Diabetes Institute (AU)
Venue
European Heart Journal
Published
2012-04-16
Volume
33
Issue
9
Pages
1058-1066
ISSN
  • 0195-668X (ISSN-L)
  • 1522-9645
OpenAlex
W2148841524
Cited by
538
References
84
Citations by year
2026: 9 · 2025: 17 · 2024: 19 · 2023: 74 · 2022: 22 · 2021: 19 · 2020: 30 · 2019: 26 · 2018: 35 · 2017: 35 · 2016: 49 · 2015: 53 · 2014: 65 · 2013: 74 · 2012: 9
FWCI
10.58
Type
journal article
Language
en
Open access
Locations
  • European Heart Journal (publishedVersion)
  • PubMed (publishedVersion)
  • BOA (University of Milano-Bicocca) (submittedVersion)
  • INFM-OAR (INFN Catania) (submittedVersion, other-oa)
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Rate Variability and Autonomic Control
  • Health Sciences › Medicine › Surgery › Cardiovascular Syncope and Autonomic Disorders
Keywords
sympathetic nervous system, essential hypertension, heart failure, resistant hypertension, beta-blockers, carotid baroreceptor stimulation, blood pressure regulation, central sympathetic outflow, diabetes risk
MeSH terms
Adrenergic beta-Antagonists, Arrhythmias, Cardiac, Autonomic Nervous System Diseases, Blood Pressure, Electric Stimulation Therapy, Equipment Design, Heart Failure, Humans, Hypertension, Insulin Resistance, Kidney Failure, Chronic, Myocardium, Norepinephrine, Receptors, Adrenergic, beta, Catheter Ablation, Hypertrophy, Left Ventricular, Baroreflex, Prostheses and Implants, Sleep Apnea, Obstructive

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review